Testing a diabetes drug for drinking and heart health in HIV
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 89 years old
- You have HIV and take your HIV medicines regularly (no missed doses for the last week)
- Your CD4 count was at least 300 in the last year
- Your body mass index (BMI) is 23 or higher
- You have had a drink in the past 3 months and your drinking level is moderate or higher
- You can get mail at a stable address for the next 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether semaglutide, a medication already used for diabetes and weight loss, can help people with HIV who also have an alcohol use disorder cut back on drinking. It is for patients treated at the Atlanta VA Healthcare System.
This study tests a very low dose of a medication called a GLP-1 receptor agonist to see if it can improve heart and metabolic health in people with HIV who have excess weight.
This study tests whether a weekly medicine called semaglutide can help veterans who drink heavily reduce their alcohol intake. If you're a veteran and want to cut down on drinking, this study may be an option.
This study tests if a medication called semaglutide (used for diabetes and weight loss) can help reduce alcohol craving and drinking. It also looks at how the drug affects stress hormones and metabolism, which may help you drink less and lose weight.
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
This study tests whether a weekly injection (a GLP-1 medication similar to semaglutide) can help people with obesity and fatty liver reduce their alcohol intake and improve liver health. It may be an option if you drink more than moderate amounts and have fatty liver.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.